Gladius Capital Management LP Buys Shares of 10,939 Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)

Gladius Capital Management LP purchased a new stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) in the 2nd quarter, HoldingsChannel reports. The fund purchased 10,939 shares of the company’s stock, valued at approximately $26,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Chicago Partners Investment Group LLC increased its stake in shares of Acumen Pharmaceuticals by 34.9% in the fourth quarter. Chicago Partners Investment Group LLC now owns 18,315 shares of the company’s stock valued at $70,000 after buying an additional 4,736 shares during the period. SG Americas Securities LLC acquired a new stake in Acumen Pharmaceuticals during the first quarter worth approximately $52,000. Susquehanna Fundamental Investments LLC acquired a new stake in Acumen Pharmaceuticals during the first quarter worth approximately $253,000. Jump Financial LLC grew its stake in Acumen Pharmaceuticals by 203.8% during the fourth quarter. Jump Financial LLC now owns 103,000 shares of the company’s stock worth $396,000 after purchasing an additional 69,100 shares during the period. Finally, Parkman Healthcare Partners LLC grew its stake in Acumen Pharmaceuticals by 20.7% during the fourth quarter. Parkman Healthcare Partners LLC now owns 603,497 shares of the company’s stock worth $2,317,000 after purchasing an additional 103,683 shares during the period. Institutional investors and hedge funds own 71.01% of the company’s stock.

Acumen Pharmaceuticals Stock Down 0.2 %

NASDAQ:ABOS traded down $0.01 on Friday, hitting $2.57. The stock had a trading volume of 129,794 shares, compared to its average volume of 381,591. The business’s fifty day moving average is $2.70 and its 200 day moving average is $3.27. The company has a market cap of $154.41 million, a PE ratio of -2.42 and a beta of 0.11. The company has a quick ratio of 30.20, a current ratio of 30.20 and a debt-to-equity ratio of 0.12. Acumen Pharmaceuticals, Inc. has a 52 week low of $1.81 and a 52 week high of $6.78.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). During the same period last year, the company posted ($0.28) earnings per share. On average, equities research analysts expect that Acumen Pharmaceuticals, Inc. will post -1.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on ABOS. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Acumen Pharmaceuticals in a research note on Wednesday. Citigroup raised Acumen Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th. Finally, UBS Group decreased their target price on Acumen Pharmaceuticals from $14.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.